Himanshu P Upadhyaya

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. pmc Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine
    Himanshu Upadhyaya
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Child Adolesc Psychiatry Ment Health 7:14. 2013
  2. pmc A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder
    Himanshu P Upadhyaya
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychopharmacology (Berl) 226:189-200. 2013
  3. doi request reprint Stimulant formulation and motivation for nonmedical use of prescription attention-deficit/hyperactivity disorder medications in a college-aged population
    Himanshu P Upadhyaya
    Eli Lilly and Company and or one of its subsidiaries, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Am J Addict 19:569-77. 2010
  4. doi request reprint Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study
    Lenard Adler
    From the New York University School of Medicine and New York VA Harbor Healthcare System, New York, NY Eli Lilly and Company, Neuroscience, Indianapolis, IN inVentiv Health Clinical, LLC, Ann Arbor, MI University of Mississippi Medical School, Jackson, MS Tufts University School of Medicine, Boston, MA Indiana University School of Medicine, Indianapolis, IN and Lilly Research Laboratories, Kobe, Japan
    J Clin Psychopharmacol 34:461-6. 2014
  5. doi request reprint A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions
    Yoko Tanaka
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    J Child Adolesc Psychopharmacol 23:262-70. 2013
  6. doi request reprint CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial
    Bonnie A Fijal
    Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Pharmacol 55:1167-74. 2015

Detail Information

Publications6

  1. pmc Baseline characteristics of European and non-European adult patients with attention deficit hyperactivity disorder participating in a placebo-controlled, randomized treatment study with atomoxetine
    Himanshu Upadhyaya
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Child Adolesc Psychiatry Ment Health 7:14. 2013
    ..This analysis examines the characteristics of adult patients with ADHD in a European (EUR) and non-European (NE) patient population...
  2. pmc A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder
    Himanshu P Upadhyaya
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Psychopharmacology (Berl) 226:189-200. 2013
    ..It was classified as an unscheduled medication indicating a low potential for abuse. However, the abuse potential of atomoxetine has not been reviewed...
  3. doi request reprint Stimulant formulation and motivation for nonmedical use of prescription attention-deficit/hyperactivity disorder medications in a college-aged population
    Himanshu P Upadhyaya
    Eli Lilly and Company and or one of its subsidiaries, Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Am J Addict 19:569-77. 2010
    ..Those using extended release (ER) stimulant formulations were less likely to endorse "staying awake" as a reason for NMU compared to those using immediate release (IR) stimulant formulations. ..
  4. doi request reprint Executive function in adults with attention-deficit/hyperactivity disorder during treatment with atomoxetine in a randomized, placebo-controlled, withdrawal study
    Lenard Adler
    From the New York University School of Medicine and New York VA Harbor Healthcare System, New York, NY Eli Lilly and Company, Neuroscience, Indianapolis, IN inVentiv Health Clinical, LLC, Ann Arbor, MI University of Mississippi Medical School, Jackson, MS Tufts University School of Medicine, Boston, MA Indiana University School of Medicine, Indianapolis, IN and Lilly Research Laboratories, Kobe, Japan
    J Clin Psychopharmacol 34:461-6. 2014
    ....
  5. doi request reprint A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions
    Yoko Tanaka
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA
    J Child Adolesc Psychopharmacol 23:262-70. 2013
    ..This meta-analysis was to assess the consistency of the treatment effect of atomoxetine across four global geographic regions...
  6. doi request reprint CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial
    Bonnie A Fijal
    Eli Lilly and Company, Indianapolis, IN, USA
    J Clin Pharmacol 55:1167-74. 2015
    ..These results suggest that data from CYP2D6 intermediate and extensive/ultrarapid metabolizers can be combined when considering safety analyses related to atomoxetine. ..